Objective:Yiqi Fumai Lyophilized Injection(YQFM),a Chinese medicine injection,has been widely used for the treatment of cardiovascular diseases,especially heart failure(HF).However,bioactive compounds and underlying m...Objective:Yiqi Fumai Lyophilized Injection(YQFM),a Chinese medicine injection,has been widely used for the treatment of cardiovascular diseases,especially heart failure(HF).However,bioactive compounds and underlying mechanisms of YQFM in treating HF remain poorly understood.Materials and Methods:Network pharmacology was employed to investigate the bioactive compounds and mechanisms of YQFM.A compound-target network was constructed to screen bioactive compounds based on contribution index calculation.Then,an adriamycin-induced HF rat model was established to evaluate the cardio-protective effects of YQFM by hematoxylin and eosin staining and enzyme-linked immunosorbent assays.Results:Network pharmacology indicated that YQFM may alleviate HF through 36 compounds and 109 targets.Particularly,ginsenosides Rb1,Rg1,Re,Rf,Rb2,Rh1,schisandrin,and ginsenoside Rc were indicated as the top contributors of YQFM in treating HF.YQFM was predicted to act on multiple targets such as vascular endothelial growth factor A,interleukin-2(IL-2),IL-6,and IL-1β,as well as to regulate signaling pathways such as hypoxia-inducible factor 1,tumor necrosis factor,VEGF,and PI3K-Akt.The pharmacological study suggested that YQFM could attenuate cardiac injury and up-regulate plasma concentrations of VEGFR-1 and NO in HF rats.Ginsenoside Rb1,as the major contributor from network pharmacology analysis,also showed a cardioprotective effect and up-regulation of VEGFR-1 in plasma.Conclusions:Ginsenosides and schisandrin were predicted as the most important contributors to the cardioprotective effect of YQMF.Ginsenoside Rb1 was proved to alleviate HF and increase the plasma concentration of VEGFR-1.展开更多
目的系统评价注射用益气复脉(冻干)联合常规西药治疗心力衰竭的临床疗效。方法计算机检索中国知网、万方数据库PubMed等数据库自建库以来至2018年12月相关的随机对照试验(RCT),经严格手工检索及质量评价后,采用Review Manger 5.3软件进...目的系统评价注射用益气复脉(冻干)联合常规西药治疗心力衰竭的临床疗效。方法计算机检索中国知网、万方数据库PubMed等数据库自建库以来至2018年12月相关的随机对照试验(RCT),经严格手工检索及质量评价后,采用Review Manger 5.3软件进行Meta分析。结果共纳入20个RCT,Jadad评分3篇为2分,17篇为1分。Meta分析结果显示:注射用益气复脉(冻干)可提高临床疗效[RR=3.06,95% CI (2.27,4.12), P <0.000 01)];增加左室射血分数[MD=5.34,95% CI (1.35,9.32), P =0.009];减少左室舒张末内径[MD=-2.39,95% CI (-4.46,-0.32), P =0.02];增加6 min步行距离[MD=69.44,95% CI (60.61,78.28), P <0.000 01];降低N末端B型钠尿肽原(NT-proBNP)水平[MD=-216.15,95% CI (-256.67,-175.63), P <0.000 01];降低B型利钠肽(BNP)水平[MD=-57.05,95% CI (-77.16,-36.94 ), P <0.000 01]。结论注射用益气复脉(冻干)联合常规西药治疗心力衰竭可提高临床疗效,改善心功能。展开更多
基金supported by the National Key Research and Development Program of China(No.2017YFC1700400,2017YFC1700405)the National Natural Science Foundation of China(No.81921001,82122073)。
文摘Objective:Yiqi Fumai Lyophilized Injection(YQFM),a Chinese medicine injection,has been widely used for the treatment of cardiovascular diseases,especially heart failure(HF).However,bioactive compounds and underlying mechanisms of YQFM in treating HF remain poorly understood.Materials and Methods:Network pharmacology was employed to investigate the bioactive compounds and mechanisms of YQFM.A compound-target network was constructed to screen bioactive compounds based on contribution index calculation.Then,an adriamycin-induced HF rat model was established to evaluate the cardio-protective effects of YQFM by hematoxylin and eosin staining and enzyme-linked immunosorbent assays.Results:Network pharmacology indicated that YQFM may alleviate HF through 36 compounds and 109 targets.Particularly,ginsenosides Rb1,Rg1,Re,Rf,Rb2,Rh1,schisandrin,and ginsenoside Rc were indicated as the top contributors of YQFM in treating HF.YQFM was predicted to act on multiple targets such as vascular endothelial growth factor A,interleukin-2(IL-2),IL-6,and IL-1β,as well as to regulate signaling pathways such as hypoxia-inducible factor 1,tumor necrosis factor,VEGF,and PI3K-Akt.The pharmacological study suggested that YQFM could attenuate cardiac injury and up-regulate plasma concentrations of VEGFR-1 and NO in HF rats.Ginsenoside Rb1,as the major contributor from network pharmacology analysis,also showed a cardioprotective effect and up-regulation of VEGFR-1 in plasma.Conclusions:Ginsenosides and schisandrin were predicted as the most important contributors to the cardioprotective effect of YQMF.Ginsenoside Rb1 was proved to alleviate HF and increase the plasma concentration of VEGFR-1.
文摘目的系统评价注射用益气复脉(冻干)联合常规西药治疗心力衰竭的临床疗效。方法计算机检索中国知网、万方数据库PubMed等数据库自建库以来至2018年12月相关的随机对照试验(RCT),经严格手工检索及质量评价后,采用Review Manger 5.3软件进行Meta分析。结果共纳入20个RCT,Jadad评分3篇为2分,17篇为1分。Meta分析结果显示:注射用益气复脉(冻干)可提高临床疗效[RR=3.06,95% CI (2.27,4.12), P <0.000 01)];增加左室射血分数[MD=5.34,95% CI (1.35,9.32), P =0.009];减少左室舒张末内径[MD=-2.39,95% CI (-4.46,-0.32), P =0.02];增加6 min步行距离[MD=69.44,95% CI (60.61,78.28), P <0.000 01];降低N末端B型钠尿肽原(NT-proBNP)水平[MD=-216.15,95% CI (-256.67,-175.63), P <0.000 01];降低B型利钠肽(BNP)水平[MD=-57.05,95% CI (-77.16,-36.94 ), P <0.000 01]。结论注射用益气复脉(冻干)联合常规西药治疗心力衰竭可提高临床疗效,改善心功能。
